Rybelsus one-year results: what the science says vs. TikTok

What's this video probably claiming?

Based on the caption and hashtags, @la_adriana01 is sharing a one-year personal update on taking Rybelsus (oral semaglutide) for what appears to be type 2 diabetes management, with weight loss as a visible secondary outcome. The hashtags reference A1C, high blood pressure, and the Spanish-language weight loss community, suggesting she's reporting improvements across multiple metabolic markers. This format, the casual one-year check-in with before/after framing, is one of TikTok's most popular GLP-1 content formats. Viewers are almost certainly getting claims about meaningful weight dropped, A1C numbers improving, and possibly blood pressure coming down. Whether she's framing Rybelsus as a diabetes drug that also caused weight loss, or primarily as a weight loss tool, matters a lot clinically, and that distinction tends to get blurry in these videos.

What does the science actually show?

Oral semaglutide 14 mg daily was studied in the PIONEER program. PIONEER 1 (Aroda et al., 2019, Diabetes Care) showed A1C reductions of 1.4 percentage points versus 0.2 for placebo over 26 weeks. Weight loss in that trial averaged around 2.6 kg at the 14 mg dose, which is modest compared to injectable semaglutide. PIONEER 4 compared oral semaglutide to liraglutide and found similar glycemic control but oral semaglutide edged ahead on weight. The STEP trials used injectable semaglutide 2.4 mg and showed average weight loss of 14.9% body weight over 68 weeks (Wilding et al., 2021, NEJM), but Rybelsus is dosed at a maximum 14 mg orally and has significantly lower bioavailability, roughly 1% absorption under fasting conditions. One year of consistent use can produce real results, but they are not equivalent to injectable formulations.

Where does the social media noise diverge from clinical reality?

The biggest divergence here is the oral versus injectable semaglutide confusion. TikTok audiences regularly conflate Rybelsus results with Ozempic or Wegovy results because they are all "semaglutide." They are not the same drug in practice. Oral semaglutide requires strict fasting administration, a small amount of water only, and a 30-minute wait before eating. Non-compliance with those instructions dramatically reduces absorption. Most TikTok testimonials do not address adherence to dosing protocol at all. There is also a tendency to credit all metabolic improvements to the GLP-1 agonist without accounting for dietary changes, which almost always accompany GLP-1 use due to appetite suppression. A1C improvements and blood pressure changes are real but multifactorial. Presenting them as a direct drug effect alone is an oversimplification that can mislead viewers who expect identical outcomes.

What should you actually know?

Rybelsus is FDA-approved for type 2 diabetes in adults, not for weight loss as a primary indication. That is what Wegovy is for. If you are taking Rybelsus and experiencing weight loss, that is a real and documented pharmacological effect, but the dose ceiling of 14 mg oral semaglutide produces more conservative weight outcomes than the 2.4 mg weekly injectable. Real-world data from one-year users is genuinely valuable, and patient-reported A1C and blood pressure improvements align with what the PIONEER trials showed. The GI side effects, nausea especially, tend to front-load in the first 8 to 12 weeks and often improve. Anyone watching this video and thinking about starting semaglutide should know that individual results vary widely, that the oral form has strict administration requirements, and that a prescribing clinician needs to evaluate whether the diabetes indication, the weight management indication, or both apply to their specific case.